Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes

• Status: Terminated
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of the trial is to compare insulin detemir once daily to NPH insulin once daily as measured by blood sugar control in ageing subjects with type 2 diabetes naive to previous insulin therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Insulin naive

• Treatment with oral anti-diabetic drugs (OADs) for at least 3 months and not achieving therapeutic targets

• HbA1c between 8% - 10.5%

Exclusion Criteria:

• Secondary diabetes, MODY (Maturity Onset Diabetes of the Young)

• Previous treatment with insulin (except for short-term treatment with insulin for intercurrent illness as judged by the Investigator)

• Proliferative retinopathy, maculopathy requiring treatment,

• Hypoglycaemia unawareness as judged by the Investigator, recurrent major hypoglycaemia

• End stage liver disease (increased liver enzymes 4 fold), end stage renal disease assessed by MDRD (Modification of Diet in Renal Disease) less than 30 ml/min or dialysed patient, acute heart failure, any acute cardiovascular event or cerebrovascular event less than 6 months

• Acute disease with poor prognosis

• History of alcoholism, drug abuse, or psychiatric disease or personality disorders likely to invalidate voluntary consent or to prevent good compliance with the trial protocol

• Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation (patients having a score of less than 15 in a previous MMSE (Mini-Mental State Examination) in the last six months) and any conditions as judged by the investigator

• Legal incapacity or limited legal capacity (patients under guardianship or curatorship)

• Concomitant medication for Alzheimers treatment (Memantine, Anticholinesterasique treatment)

• Participation in another clinical trial less than one month before inclusion in this trial

• Illness requiring repeated hospitalisation

• Known or suspected allergy to the insulin or any compositional component

• Anticipated change or new use in concomitant medication known to interfere with glucose metabolism, such as systemic corticotherapy more than 5 mg/day (prednisone)

• Any other condition that the Investigator feels would interfere with trial participation or evaluation of results

• Terminal illness